Department of Obstetrics and Gynecology, University of Szeged, Hungary.
Climacteric. 2012 Feb;15(1):93-4. doi: 10.3109/13697137.2011.604143. Epub 2011 Dec 1.
The aromatase inhibitor anastrazole proved effective in the treatment of endometrial hyperplasia and postmenopausal bleeding in an obese 65-year-old woman with high operative risk. During anastrazole administration for 12 months, the endometrial thickness decreased from 9.8 mm to 2.4 mm and the control endometrial histology showed an atrophic endometrium. Uterine bleeding did not occur in the post-treatment, 3-year follow-up period. The endometrial thicknesses measured yearly by ultrasonography were 2.9, 3.5 and 3.3 mm. The plasma estradiol levels increased from < 73 pmol/l post-treatment to 112, 98 and 103 pmol/l. This case demonstrates that long-term aromatase inhibitor treatment can result in a refractory status of the endometrium and the estradiol produced in the adipose tissue does not exert a proliferative effect.
芳香酶抑制剂阿那曲唑在治疗一名 65 岁肥胖、高手术风险的绝经后妇女的子宫内膜增生和绝经后出血方面非常有效。在接受阿那曲唑治疗 12 个月期间，子宫内膜厚度从 9.8 毫米减少到 2.4 毫米，且控制内膜组织学显示为萎缩性子宫内膜。在治疗后 3 年的随访期间，未出现子宫出血。通过超声每年测量的子宫内膜厚度分别为 2.9、3.5 和 3.3 毫米。血浆雌二醇水平从治疗后<73pmol/l 增加到 112、98 和 103pmol/l。本病例表明，长期使用芳香酶抑制剂治疗可能导致子宫内膜的抗药性状态，而脂肪组织中产生的雌二醇不会产生增殖作用。
